Dr Christian Behrenbruch

Telix Pharmaceuticals strikes $3.3b merger with German radioisotope giant ITM

Melbourne's Telix Pharmaceuticals will merge with German radioisotope maker ITM in a deal worth as much as $3.3 billion, keeping about 76 per cent ownership with existing Telix shareholders once completed.

Also Biotech Dispatch

Guided nuclear missile for cancer: Telix prepares for Nasdaq IPO

Telix, an ASX-listed radiopharmaceutical maker headquartered in Melbourne, is preparing a dual US listing; the piece also covers revenue growth, cancer trial results and recalls its 2017 float.